快驗保 MED 深 滬
已收盤 02-06 16:00:00 美东时间
11.36
+0.530
+4.89%
華盛通- 最 高11.61
- 今 開10.82
- 成交量 36.86万股
- 最 低 10.82
- 昨 收 10.83
- 總市值 1.25亿
- 52周最高 16.4489
- 市盈率 靜 59.57
- 換手率 3.35%
- 52周最低 10.10
- 委 比 -75.44%
- 總股本 1099.13万
- 歷史最高 321.22
- 量 比 1.49
- 振 幅 7.29%
- 歷史最低 -17.07
- 每 手 1
- 風險率 1.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Medifast Inc. to Announce Financial Results
Medifast Inc. to Announce Financial Results Medifast Inc. will announce its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, February 17, 2026, after market close. Results will be released on the Investor Relations section of Medifast's website at https://w
02-04 05:05
Medifast Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht
Medifast Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht Medifast Inc. wird die Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2025 am Dienstag, den 17. Februar 2026, nach Börsenschluss bekannt geben. Die Ergebnisse werden im Investor Relations Bereich der Medifast-Webs
02-04 05:05
Medifast Appoints Nicholas Johnson President, Effective Immediately; CEO Dan Chard To Step Down In June
Medifast, Inc. (NYSE: MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health.Medifast Chairman & Chief
01-05 22:05
UPDATE: Medifast Q2 EPS $0.22 Beats $(0.22) Estimate, Sales $105.600M Beat $96.100M Estimate
Medifast (NYSE:MED) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $(0.22) by 200 percent. This is a 76.09 percent decrease over earnings of $0.92 per share from the same
2025-08-05 05:58
Medifast Q3 expected to be more than $(0.60) vs $(0.30) Est; Sees Q3 Sales $70.000M-$90.000M vs $93.800M Est
Medifast (NYSE:MED) Q3 expected to be more than $(0.60) vs $(0.30) Est. sees Q3 sales of $70.000 million-$90.000 million vs $93.800 million analyst estimate.
2025-08-05 04:08
Medifast projects Q2 2025 revenue of $85M-$105M amid coach strategy enhancements
Earnings Call Insights: Medifast (MED) Q1 2025 Management View CEO Dan Chard emphasized the company's focus on the evolving weight-loss market, highlighting the relevance of Medifast's OPTAVIA program...
2025-04-29 06:04
美股大行评级 | 潜在涨幅147%！SLDB获机构升目标价至16美元，维持“买入”评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1099253771533127680.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Stoke Therapeutics(STOK)"买入"评级，目标价从35美元升至47美元</p> <p>• D. Boral Capital：上调CervoMed(CR
2025-02-20 09:10
Medifast Faces Revenue Challenges Amid New Product Launch
Medifast (($MED)) has held its Q4 earnings call. Read on for the main highlight...
2025-02-20 08:20
